FierceBiotech

Rhythm’s phase 2 obesity pill trial hits primary endpoint, sending stock up

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. A phase 2 trial of the biotech’s next-generation oral candidate hit its primary endpoint, sending the stock ...
Seeking Alpha

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...